Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications
February 22, 2024 08:30 ET
|
Ashvattha Therapeutics
The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis,...
Ashvattha Therapeutics to Participate in Upcoming Investor Conferences
February 14, 2024 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
Ashvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operations
January 04, 2024 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences
November 20, 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study
November 01, 2023 08:30 ET
|
Ashvattha Therapeutics
Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME)Favorable safety and...
Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations
October 09, 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
Ashvattha Therapeutics Presents Promising Preclinical Data on New Dendranib Nanomedicine Candidate ASH41020 at the 16th International Society of Neuroimmunology Congress (ISNI)
August 22, 2023 08:30 ET
|
Ashvattha Therapeutics
Data demonstrated that ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, directs macrophage polarization toward the anti-inflammatory M2 phenotypeASH41020 treatment lessened disease...
Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on New ‘Dendranib’ Nanomedicine Candidate at the 16th International Society of Neuroimmunology Congress (ISNI)
August 15, 2023 08:30 ET
|
Ashvattha Therapeutics
Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple sclerosis REDWOOD CITY, Calif.,...
Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors
May 31, 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers...
Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting
April 26, 2023 13:30 ET
|
Ashvattha Therapeutics
Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions to a level comparable to D-4517.2 delivered subcutaneously and Aflibercept...